Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Amarin Corporation PLC (AMRN)

NASDAQ
Symbol
Exchange
Currency
AMRNNASDAQUSD
AMRNyFrankfurtEUR
Currency in USD
Disclaimer
0.879
-0.005(-0.53%)
Closed
After Hours
0.908+0.029(+3.311%)

AMRN Comments

Time to buy
Great opportunity
anybody has strategy how to play this stock going forward given this news
Typically after a litigation loss, there's a drop and recovery. But this company is not diverse in product. there is an appeal process, and always a potential for some kind of settlement during the appeal, plus I don't believe this affect sales overseas. So I think this is going to drop today when people have to minimize losses and if it's under $5, certain funds can't hold it. I would expect in the next few weeks to see it recover a bit while people play the appeal
Yeah sell the stock. What are they going to do to regain a increase of 140% to breakeven your losses? They lost their bread and butter. Especially in an environment we are in right now. They are going to reverse split and they are going bankrupt.
This is actually a very real possibility, I agree.
that's depressing
Biopharma company Amarin's (NASDAQ:AMRN) recently approved fish-oil-based drug, Vascepa -- its sole product -- is expected by many analysts to become a blockbuster treatment for people at risk of heart attacks and strokes. However, with the COVID-19 pandemic dominating most people's concerns, the company announced Monday that it would be withdrawing its field sales force until March 30. The biotech company had originally planned to heavily promote Vascepa in 2020, and had doubled its sales force to around 800 in preparation for the expected sales push. However, many analysts are now expecting that Vascepa sales will flatten or possibly decline in the next quarter or two as COVID-19 holds the attention of patients and physicians, and worries like high triglycerides seem less pressing.
sold all of my positions. this stock barely moves. it overreacts to bad news and barely reacts to good news. I've held this stock for almost 2.5 years now and it just floats around $17-$19. I've missed many opportunities on other stocks
Say the first word that comes to mind of AMRN. To me it's languish.
It was only in mid-2018 that AMRN made the move from 2-3 $ to 16-20$, so if you held for over 2 years, you've made a kiIIing! It has been relatively quiet since that, but the market cap is so high already that targets of $30-35+ seem very speculative.
Lmfaoooo thank goodness
With the proceedings completed, and Dr. Reddy's and Hikma having presented their best case, Yee is now more confident that Amarin is likely to prevail, "removing the chief overhang on the stock." Amarin shares have been relatively range bound the last month despite positive news on the competitive front with two key competitor trials having failed, Yee contends. He attributes this to uncertainty associated with the patent trial and the potential risk for Reddy's and Hikma, two prospective generics for Amarin's Vascepa, to present some "bombshell" evidence. However, the analyst now thinks it will be hard for the judge to not rule in favor of Amarin. Yee sees the stock up 10%-20% on a positive ruling and keeps a Buy rating on Amarin with a $30 price target. The stock closed Tuesday at $20.26.
Amarin, AstraZeneca, Acasti Pharma analyst commentary at Roth Capital  Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital. Roth Capital analyst Yasmeen Rahimi maintained a Buy rating and $31 price target on Amarin (AMRN) following the failures of two competitors to Amarin's Vascepa -- those being the discontinuation of AstraZeneca's (AZN) Epanova trial and the negative TRIOLOGY 1 data from Acasti Pharma's (ACST) CaPre -- which leaves Vascepa as the "'go-to' omega-3 product" and kills the central bear case against Amarin.. . Read more at: . https://thefly.com/landingPageNews.php?id=3017149
Good news for Amarin. The bad news for Epanova was good news for Amarin. The drugmaker received FDA approval in December 2019 for an updated label for Vascepa indicating that it reduces cardiovascular risk. Analysts expect Vascepa will generate blockbuster sales with this new label -- and it now won't face competition from AstraZeneca.
Citi analyst Joel Beatty attributes the selloff today in shares of Amarin (AMRN) to reports stating that UnitedHealth (UNH) dropped Vascepa from its preferred list for 2020. However, after comparing 2019 and 2020 documents for a few UnitedHealth plans, Beatty did not find any examples of changes in tiering or other preferential status for Vascepa. Payers likely haven't yet considered the new "game-changing" cardiovascular risk-reduction label for Vascepa that was granted in December, which leaves Vascepa with no relevant competitors, Beatty tells investors in an intraday research note. As a result, the analyst, who keeps a Neutral rating on Amarin, views today's share pullback as unwarranted. The move creates a lower entry point for those investors looking to buy the stock, says Beatty. Amarin in afternoon trading is down 6%, or $1.15, to $18.93.. . Read more at: . https://thefly.com/landingPageNews.php?id=3014881
Patience
Cantor Fitzgerald analyst Louise Chen said she believes the 5% pullback in Amarin (AMRN) shares is related to headlines that there is a document that says Vascepa has been deemed by UnitedHealth (UNH) to be a "non-preferred" drug that requires prior authorization. However she said the drugmaker confirmed that "this is old news" since UnitedHealth has always been an outlier. If anything, she believes the reimbursement situation with UnitedHealth "could get better quickly" now that Vascepa has a broad label and she views the pullback amid this "noise" could be a good buying opportunity. Chen maintains an Overweight rating and $35 price target on Amarin shares.. . Read more at:. https://thefly.com/landingPageNews.php?id=3014849
thanks for news!
Interesting, in that case today's drop may be shortlived. To be fair though, most of the biotech stock I follow have been noticeably down today, even on no news.
who know ? what happen..? why is so low price..?
UnitedHealthcare dropped Amarin's vascepa from preferred list
 is there any hope for growth?
 I heard it was fake news.
Don't let fear cost you money, hold on for the upcoming ride!
amrn $50 price target
Max price is 22$
Curiously sane pre-market today. It's like the market understands FDA approval is already priced in.
Earnings is Feb 26. Might be an earnings plays
Someone just bought 500 calls fro Amarin for March. Hedge or insider or bluff?
Recovered in a week from institutional sabotage. I'm mildly curious on how much those who knew about the report made. The rest of us at least got the dip.
uh. well not quite yet
it took a week longer but now its on like donkey kong
Well played by Oppenheimer. Conveniently by an individual analyst while the institution took a large short position.. . . It could have been believable. But they decided to paint the absolutely worst case contrarian scenario so it comes off as plain market manipulation.
Why is it being attacked in pre-market?
Oppenheimer PT of $7 will have a short-term impact for sure.
Oppenheimer PT of $7 will have an impact for sure.
Powerful product. Can save lives, full approval coming in several weeks (end of Dec.).
$35 price target for Dec. 28th. Long
News is actually getting out and the attention amrn longs are deserving! Shorts will be hung out to dry this upcoming week!
$35 at opening ?
...
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.